Bevacizumab plus platinum-based chemotherapy: In advanced non-small cell lung cancer

BioDrugs

Volumn 23, Issue 3, 2009, Pages 187-196

  Wagstaff, Antona J ^a,b   Keam, Susan J ^a,b   McCormack, Paul L ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; GEMCITABINE; LOW MOLECULAR WEIGHT HEPARIN; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; VASCULOTROPIN;

ADD ON THERAPY; ADVANCED CANCER; ANTICOAGULANT THERAPY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; COST CONTROL; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEBRILE NEUTROPENIA; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GROUPS BY AGE; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPONATREMIA; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; METASTASIS INHIBITION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; REPEATED DRUG DOSE; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS;

EID: 68549097891     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/00063030-200923030-00005     Document Type: Review

References (50)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001 Sep; 2: 533-43
2. Herbst RS, Sandler AB. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?. Oncologist 2004; 9 Suppl. 1: 19-26
3. Spicer J, Harper P. Targeted therapies for non-small cell lung cancer. Int J Clin Pract 2005 Sep; 59 (9): 1055-62
4. National Cancer Institute. Non-small cell lung cancer: treatment (PDQ®) health professional version [online]. Available from URL: http://www.cancer. gov [Accessed 2009 Jun 25]
5. Di Costanzo F, Mazzoni F, Micol Mela M, et al. Bevacizumab in non-small cell lung cancer. Drugs 2008; 68 (6): 737-46
6. Cascone T, Troiani T, Morelli MP, et al. Antiangiogenic drugs in non-small cell lung cancer treatment. Curr Opin Oncol 2006 Mar; 18 (2): 151-5
7. Lyseng-Williamson KA, Robinson DM. Bevacizumab: a review of its use in advanced colorectal cancer, breast cancer, and NSCLC. Am J Cancer 2006; 5 (1): 43-60
8. Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7: 335-45
9. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997 Oct 15; 57: 4593-9
10. Gerber H-P, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005 Feb 1; 65 (3): 671-80
11. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19 (3): 843-50
12. Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab: an Eastern Cooperative Oncology Group study. Clin Cancer Res 2008 Mar 1; 14 (5): 1407-12
13. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001; 19 (3): 851-6
14. Hsei VC, Novotny WF, Margolin K, et al. Population pharmacokinetic (PK) analysis of bevacizumab (BV) in cancer subjects [abstract no. 272]. Proc Am Soc Clin Oncol 2001 May 12; 20 (Pt 1): 69a
15. Herbst RS, Mininberg E, Henderson T, et al. Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer [abstract no. 977]. EJC Supplements 2003 Sep; 1 (5): S293. Plus poster presented at the 12th European Cancer Conference; 2003 Sep 21-23; Copenhagen
16. Roche Products Limited. Avastin 25mg/mL concentrate for solution for infusion. UK summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2009 May 20]
17. Genentech Inc. Avastin® (bevacizumab) US prescribing information [online]. Available from URL: http://www.gene.com/gene/products/information/pdf/ avastin-prescribing.pdf [Accessed 2009 Jul 3]
18. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 Dec 14; 355 (24): 2542-50
19. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27 (8): 1227-34
20. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22 (11): 2184-91
21. Lilenbaum R, Raez L, Tseng J, et al. Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol 2008 May; 3 (5): 511-5
22. Dalsania CJ, Hageboutros A, Harris E, et al. Phase II trial of bevacizumab plus pemetrexed and carboplatin in previously untreated advanced nonsquamous non-small cell lung cancer [abstract no. 18163]. J Clin Oncol 2007; 25 (18 Suppl.)
23. William Jr WN, Kies MS, Fossella FV, et al. Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer [abstract no. 18098]. J Clin Oncol 2007; 25 (18 Suppl.)
24. Cobo M, Ferrer N, Paredes A, et al. Bevacizumab (Avastin®) in combination with cisplatin and docetaxel as first line treatment of patients (P) with advanced or metastatic, non squamous, non-small-cell lung cancer (NSCLC) [abstract no. 244P]. Ann Oncol 2008 Sep; 19 Suppl. 8: viii95
25. Waples JM, Auerbach M, Steis R, et al. A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (an International Oncology Network study, #1-04-015) [abstract no. 19018]. J Clin Oncol 2008; 26 (15 Suppl.): 707s
26. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. Epub 2009 May 11
27. Crino L, Mezger J, Griesinger F, et al. MO19390 (SAiL): safety and efficacy of first-line bevacizumab (BV)-based therapy in advanced non-small cell lung cancer (NSCLC) [abstract no. 8043]. J Clin Oncol 2009; 27 (15 Suppl.): 417s. Plus poster presented at the American Society of Clinical Oncology (ASCO) 45th Annual Meeting; 2009 May 29-Jun 2; Orlando (FL)
28. Manegold C, von Pawel J, Zatloukal P, et al. BO17704 (AVAIL): a phase III randomised study of first-line bevacizumab combined with cisplatin/ gemcitabine (CG) in patients (pts) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC) [abstract no. LBA1]. Ann Oncol 2008 Sep; 19 Suppl. 8: viii1
29. Sandler AB, Kong G, Strickland D, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) study E4599 of bevacizumab (BV) with paclitaxel/carboplatin (PC) for advanced non-small cell lung cancer (NSCLC) [abstractno. 133]. Journal ofThoracic Oncology 2008; 3 (11 Suppl. 4): S283. Plus poster presented at the International Association for the Study of Lung Cancer (IASLC) Chicago Multidisciplinary Symposium in Thoracic Oncology; 2008 Nov 13-15; Chicago (IL)
30. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group trial 4599. J Clin Oncol 2008 Jan 1; 26 (1): 60-5
31. Grusenmeyer PA, Gralla RJ. Examining the cost and cost-effectiveness of adding bevacizumab to carboplatin and paclitaxel in advanced non-small cell lung cancer [abstract no. 6057]. J Clin Oncol 2006; 24 (18 Suppl.): 314s
32. Leighl NB, Zatloukal P, Mezger J, et al. Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study [abstract no. 8050]. J Clin Oncol 2009; 27 (15 Suppl.): 419s. Plus poster presented at the American Society of Clinical Oncology (ASCO) 45th Annual Meeting; 2009May 29-Jun 2; Orlando (FL)
33. Mezger J, von Pawel J, Reck M. Bevacizumab (Bv) single-agent maintenance following Bv-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): results from an exploratory analysis of the AVAiL study [abstract no. e19001]. J Clin Oncol 2009; 27 (15 Suppl.)
34. Heigener DF, Wiesner C, Aultman R. A cost analysis of treatment with bevacizumab plus cisplatin and gemcitabine (BCG) versus cetuximab plus vinorelbine and cisplatin (CVC) in patients with advanced or recurrent non-small cell lung cancer (NSCLC) in Germany [abstract no. e17553]. J Clin Oncol 2009; 27 (15 Suppl.)
35. Chouaid C, Vergnenègre A, Florentin V, et al. Analysis of the costs of bevacizumab plus cisplatin and gemcitabine versus cetuximab plus vinorelbine and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) in France: results from a cost modelling study [abstract no. e17560]. J Clin Oncol 2009; 27 (15 Suppl.)
36. Nuijten M, Chouaid C, Vergnenegre A. The cost savings associated with bevacizumab plus cisplatin and gemcitabine (bevacizumab-based therapy) compared with cetuximab plus vinorelbine and cisplatin (cetuximab-based therapy) in patients with advanced or recurrent non-small cell lung cancer (NSCLC) across four European countries [abstract no. PCN29]. Value Health 2009; 12 (3): A41
37. Nuijten M. The costs of treating patients with advanced or recurrent non-small cell lung cancer (NSCLC) with bevacizumab plus cisplatin and gemcitabine compared with pemetrexed plus cisplatin in induction and maintenance therapy in Germany and Italy [abstract no. PCN30]. Value Health 2009; 12 (3): A41
38. Archer V, Reck M, Sandler A, et al. Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab-based first-line therapy [poster no. 51C]. American Society of Clinical Oncology (ASCO) 44th Annual Meeting; 2008 May 30-Jun 3; Chicago (IL)
39. Hirsh V, Ramlau R, von Pawel J, et al. Final safety results of BO17704 (AVAiL): a phase III randomised study of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) [abstract no. 8039]. J Clin Oncol 2009; 27 (15 Suppl.): 416s. Plus poster presented at the American SocietyofClinical Oncology(ASCO)45th Annual Meeting; 2009 May 29-Jun2; Orlando (FL)
40. Jager E, Wu Y, Mezger J, et al. Safety of first-line bevacizumab (BV) plus chemotherapy in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL) study [poster no. 240P]. 33rd European Society for Medical Oncology (ESMO) Congress; 2008 Sep 12-16; Stockholm
41. Griesinger F, Laskin J, Pavlakis N. Safety of first-line bevacizumab-based therapy with concomitant cardiovascular or anticoagulation medication in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in MO19390 (SAiL) [poster no. 42D]. The MO19390 (SAiL) study group. American Society of Clinical Oncology (ASCO) 44th Annual Meeting; 2008 May 30-Jun 3; Chicago (IL)
42. Tsai G-M, Thatcher N. Effects of diagnostic method and surgery on safety of first-line bevacizumab plus chemotherapy in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL) [poster no. 43E]. The MO19390 (SAiL) study group. American Society of Clinical Oncology (ASCO) 44th Annual Meeting; 2008 May 30-June 3; Chicago (IL)
43. Pavlakis N, Hirsh V, Reck M, et al. MO19390 (SAiL): incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC) [abstract no. e19003]. J Clin Oncol 2009; 27 (15 Suppl.)
44. Garrido Lopez P, Laskin J, Jiang G, et al. MO19390 (SAiL): incidence and management of hypertension (HTN) during bevacizumab (Bv)-based first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract no. e19002]. J Clin Oncol 2009; 27 (15 Suppl.)
45. Fischbach NA, Spigel D, Brahmer J, et al. Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: a bevacizumab (BV) treatment observational cohort study (OCS) [abstract no. 8040]. J Clin Oncol 2009; 27 (15 Suppl.): 416s
46. Sandler A, Archer V, Hirsh V, et al. Retrospective study of clinical and radiographic risk factors associated with early-onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC) [poster no 8074]. American Society ofClinical Oncology (ASCO) 44th Annual Meeting; 2008 May 30-Jun 3; Chicago (IL)
47. Rohr UP, Augustus S, Lasserre SF, et al. Safety of bevacizumab in patients with metastases tothe central nervous system [abstract no. 2007].J Clin Oncol 2009; 27 (15 Suppl.): 88s
48. Akerley W, Langer C, Oh Y,et al. Acceptable safety ofbevacizumab therapy in patients with brain metastases due to non-small cell lung cancer [poster no. 8043]. American Society of Clinical Oncology (ASCO) 44th Annual Meeting; 2008 May 30-Jun 3; Chicago (IL)
49. F. Hoffmann-La Roche Ltd. Avastin label updated reflecting confidence in safety profile: contraindication for patients with untreated brain metastases removed [media release]. Available from URL: http://www.roche.comhttp:// www.roche.com/investors/ir-update/inv-update-2009-03-31.htm [Accessed 2009 Jul 3]
50. Hirsh V. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer. Clinical Lung Cancer 2008; 9 Suppl. 2: S62-70